News

PipelineReview.com12h
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
BASEL, Switzerland I August 11, 2025 I FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today ...
PipelineReview.com13h
AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus
SEOUL, South Korea I August 11, 2025 I AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead ...
PipelineReview.com13h
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
EAST HANOVER, NJ, USA I August 11, 2025 I Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults ...
PipelineReview.com13h
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG, China I August 10, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, ...
PipelineReview.com13h
Target selection in drug discovery: new service offering with predefined evaluation packages
STUTTGART, Germany I August 11, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of ...